Stryker Co. (NYSE:SYK) Stock Position Lifted by Plancorp LLC

Plancorp LLC lifted its holdings in Stryker Co. (NYSE:SYK) by 27.9% in the 4th quarter, HoldingsChannel reports. The firm owned 941 shares of the medical technology company’s stock after purchasing an additional 205 shares during the quarter. Plancorp LLC’s holdings in Stryker were worth $339,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of SYK. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Stryker by 4.8% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 50,506 shares of the medical technology company’s stock worth $18,246,000 after purchasing an additional 2,322 shares in the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of Stryker by 7.4% in the third quarter. Eagle Asset Management Inc. now owns 23,856 shares of the medical technology company’s stock valued at $8,969,000 after buying an additional 1,647 shares during the period. GM Advisory Group LLC acquired a new stake in shares of Stryker in the third quarter valued at $208,000. Icon Wealth Advisors LLC lifted its holdings in shares of Stryker by 461.4% in the third quarter. Icon Wealth Advisors LLC now owns 2,818 shares of the medical technology company’s stock valued at $1,018,000 after buying an additional 2,316 shares during the period. Finally, Studio Investment Management LLC acquired a new stake in shares of Stryker in the third quarter valued at $52,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.8 %

SYK opened at $371.38 on Friday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The business has a 50-day moving average of $384.28 and a 200-day moving average of $374.03. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market capitalization of $141.71 billion, a PE ratio of 47.86, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm posted $3.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Truist Financial upped their price objective on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 target price on shares of Stryker in a report on Friday. The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Finally, Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.